Lipid nanoparticles (LNPs) are one of the most significant advances in drug delivery in decades. But developing successful LNP formulations demands deep knowledge of their key building blocks: Lipids.
Before we dig into improved delivery methods, we need to acknowledge a more basic issue: women need more therapeutics in the first place. Persistent gaps exist across conditions that uniquely or disproportionally affect women. Gynecologic infections, endometriosis, the vaginal microbiome. Menopause, contraception, oncology.
As the biocatalytic toolbox expands, chemists have gained access to a wider range of catalytic options, enabling improved stereo- and regioselectivity, simplified chemical synthesis routes, improved process mass intensity (PMI), reduced environmental impact and stronger process economics.
John Tomtishen says amid shifting FDA priorities as well as developing geopolitical considerations, US companies are entering a new regulatory era, one that will define how CGTs are scaled, distributed, and delivered domestically.
Shaukat Ali, PhD, and Jim Huang, PhD, say as more NCEs are being discovered, the industry is weighing all options for evaluating those molecules in different dosages to improve solubility and oral bioavailability. With requirement for taste-masking of bitter drugs with commercially available ODT excipients, it poses additional challenges for improving taste-masking and performance of molecules for the intended usages.
Dipanwita De, PhD, and Kaspar van den Dries say solubility and bioavailability in OSD formulations remain major challenges within the early stages of drug development. While technological innovations have allowed the pharmaceutical industry to make progress in solving this hurdle, choosing formulations that help achieve desirable solubility and bioavailability can help speed up development of the most promising molecules.
Simon Bruce, MD, and Jack L. Martin, MD, indicate that as developers increasingly embrace multi-indication development, the success of multi-indication therapies will stem not merely from pipeline adjustments, but also from development strategies designed with multi-indication objectives at their core.
COMPANY PROFILE
Agno Pharmaceuticals is a leading, global, small molecule Contract Development and Manufacturing Organization (CDMO), catering to the specific needs of the branded pharmaceutical, biotech, generic, and CDMO sectors. Agno Pharmaceuticals is a US-based, end-to-end premier service provider. We specialize in supplying Registered Starting Materials (RSMs), custom Chemical Intermediates, Active Pharmaceutical Ingredients (APIs), highly potent APIs, sterile APIs, and complex Drug Product formulations (including long-acting injectables/implants) to our valued clientele worldwide. Our US-FDA inspected cGMP compliant manufacturing facilities ensures that we are able to provide our services at a level of unparalleled quality and compliance to our customer base. Click here for more.
Why Early Development Requires a Different Decision Model
Early oral drug development is an exercise in working under constraint. Teams are asked to make consequential decisions when materials are limited, timelines are tight, and the data are incomplete. Traditionally, formulation …
The white paper, Small Molecules: Choosing the Right Development Path, outlines a structured, risk-minimized approach to early CMC (Chemistry, Manufacturing, and Controls) development for small-molecule drugs—particularly for startups and virtual pharma companies with limited resources.
By: Harry Wade, Technical Associate, and Rosie Bird, EHS Lead, Catalent Dartford
The pharmaceutical industry faces a growing manufacturing challenge as therapeutic compounds become increasingly potent and targeted. Oncology and hormonal APIs, often designed for ultra-low dosing, promise meaningful clinical …
DRUG DEVELOPMENT DIRECT RESOURCES
Upcoming eNewsletter Features:
April 8 – Formulation Development
April 15 – Prefilled Syringes